SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA inspects Divis Laboratories’ Unit-II at Visakhapatnam

08 Dec 2016 Evaluate

Divis Laboratories’ Unit-II at Visakhapatnam, Andhra Pradesh has had an inspection by the US Food and Drug Administration (USFDA) from November 29, 2016 to December 06, 2016. The company has been issued a form 483 with 5 observations and these shall be responded within the time permitted.

Earlier, the company had successful inspection by the USFDA for its Unit-2 at Chippada, Bheemunipatnam near Visakhapatnam during February, 2016 with no observations.

Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.



Divis Laboratories Share Price

6562.25 -148.60 (-2.21%)
29-Jun-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1872.60
Dr. Reddys Labs. 1376.30
Cipla 1453.50
Zydus Lifesciences 1121.45
Lupin 2406.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: